Summary & Overview
HCPCS J1440: Fecal Microbiota, Live - jslm, 1 ml
HCPCS Level II code J1440 designates a live fecal microbiota product, specified as "fecal microbiota, live - jslm, 1 ml." This biologic product is used as a therapeutic material for microbiome restoration and has growing clinical and coverage relevance as fecal microbiota therapies gain regulatory approvals and clinical adoption. Nationally, clear coding supports accurate billing, coverage determinations, and tracking of utilization for these novel biologic treatments.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how this HCPCS Level II code maps to clinical service delivery, typical sites of service, and payer coverage context. The publication summarizes national benchmarks where available, common billing modifiers reported in practice, and policy developments that affect reimbursement and prior authorization practices. Clinical context on the product type and implications for procedural settings is provided to clarify where the code is typically used.
Intended for billing professionals, revenue cycle leaders, and clinical managers, the report explains coding nuances, payer considerations, and operational implications for integrating J1440 into billing workflows. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code J1440 represents fecal microbiota, live - jslm, 1 ml. This product is a biologic preparation containing live fecal microbiota intended for therapeutic use to restore gut microbial balance.
Service Type: Fecal microbiota transplantation product (biologic)
Typical Site of Service: Infusion clinic, hospital outpatient department, or specialized procedural suite
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with recurrent Clostridioides difficile infection (rCDI) or other indications for fecal microbiota transplantation (FMT) who has failed standard antibiotic therapy. The patient presents to a gastroenterology clinic or ambulatory infusion center for delivery of microbiota therapy derived from screened donor material. The clinical workflow begins with referral from the primary care provider or infectious disease specialist, donor-screened product acquisition and verification, informed consent, pre-procedure medication reconciliation (including holding offending antibiotics), and bowel preparation or colonoscopic planning if delivery will be endoscopic. Administration of J1440 (fecal microbiota, live - jslm, 1 ml) may occur via colonoscopic instillation, nasoenteric tube, enema, or encapsulated oral formulations dispensed by the pharmacy for outpatient ingestion, depending on the formulation and clinical judgment. Typical sites of service include an ambulatory surgical center, hospital outpatient department, endoscopy suite, infusion center, or outpatient clinic pharmacy for dispensation of oral capsules. Monitoring includes a short post-procedure observation period for immediate adverse reactions and scheduled follow-up to assess resolution of infection and potential delayed adverse events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no special circumstances apply to the service billed with |